Pilar Vázquez‐Rodríguez

Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

Purificación Cid‐Silva, Noelia Fernández Bargiela, Luis Margusino‐Framiñán et al. · Basic & Clinical Pharmacology & Toxicology · 2018 · 48 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

Qian Chen, Celia Perales, María Eugenia Soria et al. · Antiviral Research · 2019 · 47 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +12

Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

Luis Margusino‐Framiñán, Purificación Cid‐Silva, Ángeles Castro‐Iglesias et al. · Telemedicine Journal and e-Health · 2018 · 30 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacy Practice +17

Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study

Noelia Fernández Bargiela, Sandra Rotea-Salvo, Luis Margusino‐Framiñán et al. · European Journal of Hospital Pharmacy · 2020 · 21 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

Luis Margusino‐Framiñán, Purificación Cid‐Silva, Sandra Rotea-Salvo et al. · European Journal of Hospital Pharmacy · 2020 · 10 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17